Delivery Order SPE2DB20D1109-SPE2DB25FP73Z
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,642.64 to AmerisourceBergen Drug Corp for ACT-O-VIALS on September 3, 2025, with completion expected by September 4, 2025. This firm fixed price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,331.73 to AmerisourceBergen Drug Corp on August 8, 2025, for ACT-O-VIALS pharmaceutical products. This firm fixed-price delivery order, with an ultimate completion date of August 11, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal...
- The Defense Logistics Agency awarded a delivery order valued at $6,693.29 to AmerisourceBergen Drug Corp for ACT-O-Vials on August 19, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction typical of AmerisourceBergen's extensive portfolio of federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $21,606.60 to AmerisourceBergen Drug Corp for ACT-O-VIALS on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order represents a non-competed award under the company's existing contract vehicle and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. ACT-O-VIALS are specialized medical supply vials that support pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $8,642.64 to AmerisourceBergen Drug Corp for Act-O-Vials on July 28, 2025, with completion targeted for July 29, 2025. This firm fixed price delivery order represents a non-competitive award and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $108,033.00 to AmerisourceBergen Drug Corp for Act-O-Vials on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price contract is non-set-aside and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $8,642.64 to AmerisourceBergen Drug Corp for Act-O-Vials on July 29, 2025, with completion targeted for July 30, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under the company's larger pharmaceutical supply contract with DLA. The award specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $43,623.36 to AmerisourceBergen Drug Corp on August 9, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order, which represents a child contract under a larger indefinite delivery vehicle, was competitively awarded with no set-aside designation. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen maintains...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $11,264.90 to AmerisourceBergen Drug Corp on August 5, 2025, with a completion deadline of August 6, 2025. This firm fixed-price delivery order, classified as a child contract under the company's larger indefinite delivery vehicle with DLA Troop Support Medical, represents a competitively awarded, non-set-aside transaction. The award was made to AmerisourceBergen's Corporate Office division, headquartered...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $34,535.20 to AmerisourceBergen Drug Corp on August 27, 2025, with an ultimate completion date of August 28, 2025. This firm fixed-price, non-set-aside contract is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery order will be performed at...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP73ZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $14,404.40 to AmerisourceBergen Drug Corp for ACT-O-VIALS on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at the company's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor within the federal medical supply chain, particularly supporting military and veteran healthcare systems. This delivery order is part of the company's extensive portfolio of pharmaceutical and medical supply contracts with DLA, through which it provides brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company holds a significant $999,999,999.00 prime indefinite delivery vehicle with DLA Troop Support Medical (SPE2DX) running through December 2026, which enables flexible fulfillment of pharmaceutical supply needs for federal healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.4k | 9/11/25 |